Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.96 |
---|---|
High | 9.96 |
Low | 9.14 |
Bid | 9.10 |
Offer | 9.34 |
Previous close | 9.97 |
Average volume | 1.31m |
---|---|
Shares outstanding | 51.97m |
Free float | 50.16m |
P/E (TTM) | -- |
Market cap | 518.14m USD |
EPS (TTM) | -2.22 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 21:00 BST.
More ▼
Announcements
- 4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
- 4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
- 4DMT Announces Presentations at Upcoming Retina Conferences
- 4DMT to Participate in the 2024 Cantor Global Healthcare Conference
- 4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
- 4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
- 4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
- 4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
- 4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity
- 4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
More ▼